Velphoro (iron sucrose, sucroferric oxyhydroxide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

				URGENT	
MEMBER INFORMATION					
LAST NAME:		FIRST NAME:			
PHONE NUMBER:		DATE OF BIRTH:			
STREET ADDRESS:					
CITY:		STATE: ZIP CODE:			
PATIENT INSURANCE ID NUN	/IBER:				
FYOU ARE NOT THE PATIENT OR THE PRESCRIFOLLOWING LINK: PRIMETHERAPEUTICS.COM/	SHT (IN/CM): WEIGH BER, YOU WILL NEED TO SUBMIT A PHI DISCLO NOPP SESENTATIVE (IF APPLICABLE): YE'S PHONE NUMBER:	SURE AUTHORIZATION FORM	WITH THIS REQU	JEST WHICH CAN BE FOUND AT THE	
PRESCRIBER INFORMATION					
LAST NAME:		FIRST NAME:			
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:			
NPI NUMBER:		DEA NUMBER:			
PHONE NUMBER:		FAX NUMBER:			
STREET ADDRESS:					
CITY:		STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:			
MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS		QUANTITY:	
NEW THERAPY DURATION OF THERAPY (SPE	RENEWAL CIFIC DATES):	IF RENEWAL: DATE	THERAPY	INITIATED:	

© 2017–2024 Prime Therapeutics Management LLC, a Prime Therapeutics LLC company

CAT0029



Continued on next page.

Revision Date: 08/22/2018

Velphoro (iron sucrose, sucroferric oxyhydroxide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST	BER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:	ICD-10:			
□ Post-gastric bypass surgery □ Stage 3 to 6 chronic kidney disease (CKD) □ Other diagnosis:	ICD-10	AL INFORMATION TO SURBORT A		
PRIOR AUTHORIZATION.	: PLEASE PROVIDE ALL RELEVANT CLINIC	ALINFORMATION TO SUPPORT A		
Clinical Information: Is the requested medication being pre	scribed by a nephrologist? ☐ Yes ☐ No			
Has the patient had a trial and inadequal of the Please provide document	uate response or intolerance to calcium cation.	acetate tablets or capsules?		
Has the patient had a trial and inadequal Please provide documentation.	uate response or intolerance to Fosrenc	ol (lanthanum carbonate)? □ Yes □ No		
Has the patient had a trial and inadequal Please provide documentation.	uate response or intolerance to Renage	l (sevelamer hcl)? □ Yes □ No		
Has the patient had a trial and inadeque Please provide documentation.	uate response or intolerance to Renvela	a(sevelamer carbonate)? □ Yes □ No		
 patient is not being treat Parathyroid hormone (PTH) les with corrected calcium levels o 	oct greater than 55 mg2/dL2 greater than or equal to 9.5 mg/dL (or r s than 150 pg/ml (or less than 2 times t	he upper limit of normal) in a patient		
Are there any other comments, diagnorphysician feels is important to this rev	oses, symptoms, medications tried or fa iew?	iled, and/or any other information the		
Please note: Not all drugs/diagnosis are	e covered on all plans. This request may	be denied unless all required		



Velphoro (iron sucrose, sucroferric oxyhydroxide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification:

Date:

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents

FAX THIS FORM TO: 800-424-7640

of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX)

and arrange for the return or destruction of these documents.

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811

